Uncertainties cloud Pharmaniaga


The optimism on the new vaccine division, which hinges solely on the Sinovac vaccine, looks uncertain and makes earnings forecasts difficult.

PETALING JAYA: Earnings visibility appears murky beyond 2021 for Pharmaniaga Bhd as it has yet to get an extension for its medical supply contract from the government which expires by year-end.

Pharmaniaga is the largest listed pharmaceutical company in the country by revenue with the government’s drug and medical supply concession in-hand.

Save 30% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 9.73/month

Billed as RM 9.73 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.63/month

Billed as RM 103.60 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Asia's growing economic power shapes global derivatives market
Stocks, dollar take tariff hit; gold gets safety bid
Malaysian economy to stay resilient in 2026 on FDI, robust infrastructure investment- HSBC�
FBM KLCI slips as traders turn cautious on growing geopolitical tension
Bursa Malaysia suspends short-selling of SMRT due to price limit breach
SMRT's share price dives on sharp earnings downgrade
MAHB 2025 passenger traffic reaches 15.53mil as VM2026 kicks off
China's Q4 GDP growth slows to 3-year low, full-year pace meets official target
World markets jolted, dollar dips as Trump vows tariffs on Europe over Greenland
Oil prices steady as ebbing Iranian protests lower chance of US attack

Others Also Read